Should I buy or sell Merck KGaA stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MKGAY shares. View MKGAY analyst ratings or view top-rated stocks .

How have MKGAY shares performed in 2024?

Merck KGaA's stock was trading at $38.36 at the beginning of the year. Since then, MKGAY shares have increased by 0.0% and is now trading at $38.36. View the best growth stocks for 2024 here .

How do I buy shares of Merck KGaA?

Shares of MKGAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:MKGAY

Merck KGaA (MKGAY) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free MKGAY Stock Alerts

$38.36

0.00 (0.00%)

(As of 08/1/2017)

Compare

Today's Range: $38.36
▼
$38.36
50-Day Range: $38.36
▼
$38.36
52-Week Range: $32.53
▼
$42.02

Volume: N/A
Average Volume: 6,872 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Merck KGaA alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Merck KGaA Stock (OTCMKTS:MKGAY)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

MKGAY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MKGAY Stock News Headlines

March 19, 2024 | msn.com

Merck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate Vaccine

February 8, 2024 | finanznachrichten.de

Future Scientists in the Making: MilliporeSigma's Curiosity Cube Wraps Up 2023 Multi-Country STEM Tour

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 22, 2024 | wsj.com

Merck KGaA

January 3, 2024 | morningstar.com

Merck KGaA ADR MRKC

November 9, 2023 | markets.businessinsider.com

Merck KGaA Q3 Results Down; Now Sees FY23 Earnings In Lower Half Of Estimate Range

October 22, 2023 | msn.com

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks

October 17, 2023 | msn.com

FDA grants expanded approval for Merck's lung cancer drug Keytruda

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 16, 2023 | markets.businessinsider.com

EC Approves Merck's KEYTRUDA As Adjuvant Treatment For Non-Small Cell Lung Cancer

October 10, 2023 | msn.com

Merck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer Patients

September 28, 2023 | reuters.com

Merck's blood vessel disorder therapy receives US FDA's priority review

September 25, 2023 | msn.com

Merck and ICR enter renewed cancer drug discovery partnership

September 20, 2023 | markets.businessinsider.com

Exscientia, Merck KGaA To Discover Drug Candidates Across Oncology, Neuroinflammation & Immunology

August 3, 2023 | msn.com

Merck KGaA reports Q2 results

August 3, 2023 | markets.businessinsider.com

Merck KGaA Q2 Results Down, Cuts FY23 View; Backs FY25 Outlook

August 1, 2023 | finance.yahoo.com

Global Cell and Gene Therapy Manufacturing Services Market to 2028, Led by Catalent, Lonza, Merck KGaA, and Thermo Fisher Scientific

July 27, 2023 | benzinga.com

Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine

July 27, 2023 | msn.com

Moderna/Merck begin late-stage study of mRNA cancer vaccine

May 1, 2023 | msn.com

Barclays Maintains Merck (MRK) Overweight Recommendation

April 27, 2023 | msn.com

Merck Makes a Bold Move That Could Transform Its Business

April 27, 2023 | washingtonpost.com

Merck: Q1 Earnings Snapshot

April 27, 2023 | msn.com

Merck Gains on Q1 Beat

April 26, 2023 | msn.com

Merck Keeps Striking Out on Expanding Its Cancer-Drug Juggernaut

April 12, 2023 | wsj.com

Merck KGaA Shares Fall After US Puts Hold on New Patients in MS Drug Trial

April 10, 2023 | msn.com

Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail

April 7, 2023 | msn.com

Merck, Eisai end two Keytruda combination trials after missing main goals

See More Headlines

Receive MKGAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceuticals - Major
Sub-Industry: N/A
Current Symbol: OTCMKTS:MKGAY
CUSIP: N/A
CIK: N/A
Web: N/A
Phone: 496151720
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Belén Garijo López
Chairman-Executive Board & CEO
Marcus Kuhnert
Chief Financial Officer
Laura Matz
Chief Science & Technology Officer
Danny Bar-Zohar
Head-Research & Development
Meeta Gulyani
EVP, Head-Strategy & Business Development

Key Competitors

View All Competitors

MKGAY Stock Analysis - Frequently Asked Questions

Should I buy or sell Merck KGaA stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MKGAY shares.
View MKGAY analyst ratings or view top-rated stocks.
How have MKGAY shares performed in 2024?: Merck KGaA's stock was trading at $38.36 at the beginning of the year. Since then, MKGAY shares have increased by 0.0% and is now trading at $38.36.
View the best growth stocks for 2024 here.
How do I buy shares of Merck KGaA?: Shares of MKGAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MKGAY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial